1. Home
  2. XPEL vs SDGR Comparison

XPEL vs SDGR Comparison

Compare XPEL & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo XPEL Inc.

XPEL

XPEL Inc.

HOLD

Current Price

$53.40

Market Cap

1.4B

Sector

Industrials

ML Signal

HOLD

Logo Schrodinger Inc.

SDGR

Schrodinger Inc.

HOLD

Current Price

$17.31

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XPEL
SDGR
Founded
1999
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.4B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
XPEL
SDGR
Price
$53.40
$17.31
Analyst Decision
Buy
Analyst Count
0
10
Target Price
N/A
$24.90
AVG Volume (30 Days)
172.6K
882.6K
Earning Date
02-25-2026
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.69
N/A
Revenue
$461,460,000.00
$256,951,000.00
Revenue This Year
$16.20
$23.69
Revenue Next Year
$11.28
$20.32
P/E Ratio
$32.11
N/A
Revenue Growth
10.29
32.90
52 Week Low
$24.25
$15.99
52 Week High
$55.84
$28.47

Technical Indicators

Market Signals
Indicator
XPEL
SDGR
Relative Strength Index (RSI) 55.81 43.59
Support Level $51.93 $16.07
Resistance Level $55.84 $17.87
Average True Range (ATR) 1.89 0.72
MACD -0.24 -0.15
Stochastic Oscillator 56.39 31.20

Price Performance

Historical Comparison
XPEL
SDGR

About XPEL XPEL Inc.

XPEL Inc is a supplier of protective films, coatings, and related services to the automobile aftermarket, new car dealerships, and automobile original equipment manufacturers, or OEMs. The majority of its revenue is derived from the sale of automotive products and related services while the remainder of its revenue is derived from non-automotive products including architectural window film and marine and flat surface protection films. The majority of revenue is derived from the United States.

About SDGR Schrodinger Inc.

Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.

Share on Social Networks: